• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Aquatech Acquires Koch's Direct Lithium Extraction Business, Integrating Li-Pro™ DLE into the PEARL™ Technology Platform

    9/16/25 5:21:00 PM ET
    $A
    $EQNR
    $SLI
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Integrated oil Companies
    Energy
    Get the next $A alert in real time by email

    CANONSBURG, Pa., Sept. 16, 2025 /PRNewswire/ -- Aquatech has acquired Koch Technology Solutions' (KTS) direct lithium extraction (DLE) business, integrating the Li-Pro™ Lithium Selective Sorption (LSS) technology and extensive Li-Pro IP portfolio into the PEARL™ process technology platform.

    Aquatech and Koch logos

    The acquisition of KTS' Li-Pro LSS technology adds direct lithium extraction to Aquatech's extensive process flowsheet IP, lithium conversion and crystallization capabilities. With this addition, Aquatech's PEARL platform becomes the only commercially proven, end-to-end flowsheet solution for lithium processing. Spanning lithium extraction, purification and refining, the PEARL process technology platform delivers high-purity battery materials for electric vehicles (EV) and utility-scale electricity storage systems (ESS).

    The integration and optimization of upstream and downstream lithium processing will empower lithium resource owners with modularized process solutions at scale. This approach improves project bankability by removing process risk, accelerating project schedules and reducing the total cost of lithium production. Li-Pro LSS will be available under technology license as part of the PEARL full flowsheet licensing offerings.

    As part of the acquisition, all ongoing lithium extraction projects utilizing Li-Pro technology and associated licenses, agreements and performance guarantees will be transferred to Aquatech. This includes KTS' role in the Joint Development Agreement (JDA) with Standard Lithium Ltd. (TSXV:SLI) (NYSE:A) in the Smackover Formation, where they have completed over 12,000 operational cycles using Li-Pro technology at their demonstration plant and achieved an average lithium recovery of over 95%. It also includes a licensing agreement with Smackover Lithium, a joint venture between Standard Lithium and Equinor (NYSE:EQNR) (OSE:EQNR), for the first phase of its South West Arkansas project. The project is among the largest lithium projects in the US, with an initial phase of 22,500 tons per annum (tpa) of lithium carbonate equivalent targeting first production in 2028, with significant scope for future expansion.

    "Koch Technology Solutions has proven the Li-Pro LSS technology as a successful DLE solution, and the time has come to scale it for the market. Aquatech is uniquely placed to scale this technology and deliver it into projects as a cost competitive, end-to-end process solution, creating significant value for the lithium industry," commented Dave Dotson, President at Koch Engineered Solutions, the parent company of KTS.

    "We are confident that our legacy lithium customers will benefit from the broader offering of Aquatech. More broadly, Koch continues to maintain an active interest in the success of the technology via its investments in several key companies within the lithium minerals and lithium battery industries," said Garrett Krall, Critical Minerals & Lithium Business Leader at Koch Technology Solutions. 

     "Fragmented technology offerings increase project cost, risk and time-to-market, which has hindered the ramp-up of urgently needed critical minerals production in the Americas and Europe. Bringing Li-Pro into the PEARL technology platform solves this pressing industry need by offering the only proven full flowsheet solution that encompasses both upstream and downstream lithium processing technology," commented Venkee Sharma, Executive Chairman at Aquatech.

    Mr. Sharma continued, "We welcome the KTS Li-Pro team to Aquatech and commend them on the pioneering work done to develop Li-Pro LSS. With over 45 years of experience scaling commercially proven technologies, we are excited to evolve Li-Pro LSS both as a standalone technology offering and as part of the PEARL platform."

    About Aquatech

    Aquatech leverages innovative technology, engineering and execution leadership to solve the world's most demanding process challenges in lithium, critical minerals and industrial water. Aquatech's technology portfolio, project execution and service capabilities are grounded in a culture of performance excellence built up over four decades, with thousands of facilities using our solutions in over 60 countries.

    www.aquatech.com

    About Koch Technology Solutions

    Koch Technology Solutions (KTS) is a leader in technology licensing, delivering operating efficiency and capital productivity for licensees deploying the technologies in our portfolio. KTS partners with companies developing chemical process technologies to create attractive licensing solutions for commercial deployment, helping to bring the next generation of process technologies to the market.

    www.kochtechsolutions.com

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/aquatech-acquires-kochs-direct-lithium-extraction-business-integrating-li-pro-dle-into-the-pearl-technology-platform-302558347.html

    SOURCE Aquatech

    Get the next $A alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $A
    $EQNR
    $SLI

    CompanyDatePrice TargetRatingAnalyst
    Equinor ASA
    $EQNR
    2/5/2026$22.00 → $25.00Hold
    TD Cowen
    Equinor ASA
    $EQNR
    2/5/2026Buy → Neutral
    BofA Securities
    Agilent Technologies Inc.
    $A
    1/20/2026$180.00Buy
    HSBC Securities
    Equinor ASA
    $EQNR
    1/8/2026Hold
    Jefferies
    Agilent Technologies Inc.
    $A
    1/5/2026$160.00In-line → Outperform
    Evercore ISI
    Agilent Technologies Inc.
    $A
    12/15/2025$165.00Equal Weight → Overweight
    Barclays
    Agilent Technologies Inc.
    $A
    12/9/2025$170.00Buy
    Goldman
    Agilent Technologies Inc.
    $A
    12/2/2025$270.00Overweight
    Morgan Stanley
    More analyst ratings

    $A
    $EQNR
    $SLI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Gonsalves Rodney (Amendment)

    4/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

    10/20/23 1:07:25 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Gonsalves Rodney bought $288 worth of shares (3 units at $111.09), increasing direct ownership by 0.01% to 24,222 units (SEC Form 4)

    4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

    9/29/23 4:03:46 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $A
    $EQNR
    $SLI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: SEC Form 4 filed by V.P., Corporate Controller Gonsalves Rodney

    4/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

    1/8/26 4:05:46 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Dolsten Mikael sold $389,511 worth of shares (2,600 units at $149.81), decreasing direct ownership by 34% to 4,973 units (SEC Form 4)

    4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

    12/3/25 4:04:44 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Senior Vice President Zhang Jianmiao Mike covered exercise/tax liability with 208 shares, decreasing direct ownership by 2% to 11,639 units (SEC Form 4)

    4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

    12/1/25 4:36:53 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $A
    $EQNR
    $SLI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    TD Cowen reiterated coverage on Equinor with a new price target

    TD Cowen reiterated coverage of Equinor with a rating of Hold and set a new price target of $25.00 from $22.00 previously

    2/5/26 7:02:53 AM ET
    $EQNR
    Integrated oil Companies
    Energy

    Equinor downgraded by BofA Securities

    BofA Securities downgraded Equinor from Buy to Neutral

    2/5/26 6:53:33 AM ET
    $EQNR
    Integrated oil Companies
    Energy

    HSBC Securities initiated coverage on Agilent with a new price target

    HSBC Securities initiated coverage of Agilent with a rating of Buy and set a new price target of $180.00

    1/20/26 9:22:21 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $A
    $EQNR
    $SLI
    SEC Filings

    View All

    SEC Form 6-K filed by Equinor ASA

    6-K - EQUINOR ASA (0001140625) (Filer)

    2/13/26 6:54:56 AM ET
    $EQNR
    Integrated oil Companies
    Energy

    SEC Form 6-K filed by Equinor ASA

    6-K - EQUINOR ASA (0001140625) (Filer)

    2/10/26 6:05:04 AM ET
    $EQNR
    Integrated oil Companies
    Energy

    SEC Form DEFA14A filed by Agilent Technologies Inc.

    DEFA14A - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)

    2/6/26 7:10:03 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $A
    $EQNR
    $SLI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Agilent Announces Cash Dividend of 25.5 Cents per Share

    Agilent Technologies Inc. (NYSE:A) today announced a quarterly dividend of 25.5 cents per share of common stock. The quarterly dividend will be paid on April 22, 2026, to all shareholders of record as of the close of business on March 31, 2026. The timing and amounts of future dividends are subject to the determination and approval of Agilent's board of directors. About Agilent Technologies Agilent Technologies, Inc. (NYSE:A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent's full range of solutions includes instruments, software, services, and expertise that provide t

    2/11/26 4:15:00 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent Presents Boehringer Ingelheim With Inaugural 2025 Instrument Trade‑In Impact Award

    Award honors leadership in sustainable laboratory practices and circular economy advancement Agilent Technologies Inc. (NYSE:A) today announced that Boehringer Ingelheim has been selected as the winner of Agilent's inaugural Instrument Trade‑In Impact Award, recognizing exceptional sustainability leadership demonstrated through their participation in Agilent's trade‑in and buyback program. The annual award honors the global partner that achieves the highest sustainability impact by diverting end‑of‑life laboratory instruments from landfill and contributing to the circular use of scientific equipment. In 2025, Boehringer Ingelheim led all partners in responsible trade‑in activity, ensuri

    2/11/26 8:00:00 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma (EOC)

    Approval expands first-line PD-L1 testing to support treatment decisions with KEYTRUDA® (pembrolizumab)1, 2 Agilent Technologies Inc. (NYSE:A) today announced that the U.S. Food and Drug Administration (FDA) has approved PD-L1 IHC 22C3 pharmDx, Code SK006, as the only FDA-approved companion diagnostic indicated to aid in identifying first-line patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (EOC), whose tumors express PD-L1 and who may be eligible for treatment with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy. PD-L1 IHC 22C3 pharmDx, Code SK006, enables pathologists to assess PD-L1 expression at the time of diagnosis, supporting informed treatm

    2/11/26 6:45:00 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $A
    $EQNR
    $SLI
    Leadership Updates

    Live Leadership Updates

    View All

    Agilent Names Adam S. Elinoff as Chief Financial Officer

    Agilent Technologies Inc. (NYSE:A) today announced the appointment of Adam S. Elinoff as chief financial officer, effective Nov. 17. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251027719923/en/Adam S. Elinoff, Chief Financial Officer, Agilent Technologies Elinoff brings two decades of financial experience spanning corporate finance, investor relations, strategy and business transformation, and has a proven record of driving enterprise-wide transformations, optimizing financial operations and scaling global capabilities. He joins Agilent from Amgen, a worldwide pioneer in biotechnology, where he advanced through a series of

    10/27/25 4:15:00 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Standard Lithium Expands Leadership Team with Appointment of General Counsel

    VANCOUVER, British Columbia, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. ("Standard Lithium" or the "Company") (TSXV:SLI) (NYSE:SLI), a leading near-commercial lithium company, is announcing the appointment of Michael Lutgring as General Counsel, effective August 18, 2025. "We are excited to have Michael join our senior leadership team," said David Park, Chief Executive Officer and Director of Standard Lithium. "Michael's deep and wide-ranging experience will be critical as we strengthen our capabilities and bring further expertise in-house as we continue our growth and development as a public company." Mr. Lutgring brings over two decades of legal and strategic a

    8/18/25 8:30:00 AM ET
    $SLI
    Major Chemicals
    Industrials

    Standard Lithium Announces New VP Appointments to Expand and Strengthen Senior Management

    VANCOUVER, British Columbia, June 23, 2025 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. ("Standard Lithium" or the "Company") (TSXV:SLI) (NYSE:SLI), a leading near-commercial lithium company, is pleased to announce the appointment of Daniel Rosen as Vice President of Strategy and Investor Relations, as well as Tim Sobel as Vice President of Health, Safety, Social and Environment ("HSSE"). "We are thrilled to welcome the additions of Daniel and Tim to our leadership team," said David Park, Chief Executive Officer and Director of Standard Lithium. "Dan's strategic insight and deep experience in investor relations and capital markets, as well as Tim's extensive history in ensuring that HSSE sta

    6/23/25 8:30:00 AM ET
    $SLI
    Major Chemicals
    Industrials

    $A
    $EQNR
    $SLI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Agilent Technologies Inc.

    SC 13G/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)

    11/12/24 1:27:37 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G filed by Agilent Technologies Inc.

    SC 13G - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)

    11/12/24 11:54:03 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G filed by Agilent Technologies Inc.

    SC 13G - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)

    11/4/24 10:57:57 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $A
    $EQNR
    $SLI
    Financials

    Live finance-specific insights

    View All

    Agilent Announces Cash Dividend of 25.5 Cents per Share

    Agilent Technologies Inc. (NYSE:A) today announced a quarterly dividend of 25.5 cents per share of common stock. The quarterly dividend will be paid on April 22, 2026, to all shareholders of record as of the close of business on March 31, 2026. The timing and amounts of future dividends are subject to the determination and approval of Agilent's board of directors. About Agilent Technologies Agilent Technologies, Inc. (NYSE:A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent's full range of solutions includes instruments, software, services, and expertise that provide t

    2/11/26 4:15:00 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Equinor to commence first tranche of the 2026 share buy-back programme

    Equinor ((OSE: EQNR, NYSE:EQNR) will on 5 February 2026 commence the first tranche of up to USD 375 million of the share buy-back programme for 2026, as announced in relation with the company's fourth quarter results on 4 February 2026. In this first tranche of the share buy-back programme for 2026, shares for up to USD 123.75 million will be purchased in the market, implying a total tranche of up to USD 375 million including shares to be redeemed from the Norwegian State. The tranche will end no later than 30 March 2026. Equinor announces a share buy-back programme of up to USD 1.5 billion for 2026, including shares to be redeemed from the Norwegian State. The share buy-back programme wil

    2/4/26 12:47:09 AM ET
    $EQNR
    Integrated oil Companies
    Energy

    Equinor ASA: Key information relating to proposed cash dividend for fourth quarter 2025

    Key information relating to the proposed cash dividend to be paid by Equinor ((OSE: EQNR, NYSE:EQNR) for fourth quarter 2025. Cash dividend amount: 0.39 Announced currency: USD Last day including rights: 12 May 2026 Ex-date Oslo Børs: 13 May 2026 Ex-date New York Stock Exchange: 15 May 2026 Record date: 15 May 2026 Payment date: 27 May 2026 Date of approval: the proposed cash dividend is subject to approval by the annual general meeting of Equinor ASA on 12 May 2026. Other information: The cash dividend per share in NOK will be communicated 21 May 2026. This information is published in accordance with the requirements of the Continuing Obligations and is subject to the disclosure r

    2/4/26 12:46:27 AM ET
    $EQNR
    Integrated oil Companies
    Energy